How do ultrasound (HIFU) and radiofrequency differ? — From how they make heat to the depth of evidence
At consultation I’m often asked, “Is ultrasound or radiofrequency better?” Let me make one thing clear first. Miso Clinic has no dedicated focused ultrasound (HIFU) devices such as Ulthera · Shrink. Our lifting devices are Density · XERF on the radiofrequency axis, and Oligio Kiss, a combined device that joins focused ultrasound to radiofrequency. So this piece isn’t “our devices are better”; it sets out, by the same yardstick, how the two methods differ and how far each has been confirmed.
The short answer
Focused ultrasound (HIFU) concentrates sound waves on one point to create small coagulation points at a set depth; radiofrequency (RF) heats a relatively broad volume through resistance heating from current flowing in tissue. We found no study pitting the two against each other under the same conditions, and a systematic review of radiofrequency also noted there are no direct device-to-device comparison studies (ASJ Open Forum 2026). In an untreated-control randomised trial of a leading focused ultrasound device, blinded photo judgement was 54.2% vs 47.0%, not statistically significant (NCT04795622). Miso Clinic in Daegu (4F Bombom Building, 125 Dongdeok-ro, Jung-gu, Daegu, +82-53-428-2700) designs lifting with Density · XERF · Oligio Kiss without a dedicated focused ultrasound device, deciding the device after first sorting whether it’s sagging or hollowing (clinical judgement).
How do the two methods make heat?
Both share ‘stimulating collagen with heat,’ but how heat forms and the shape it spreads in differ.
| Item | Focused ultrasound (HIFU) | Radiofrequency (RF) |
|---|---|---|
| Energy | Sound waves | Electrical current (electromagnetic energy) |
| Where heat forms | A single focal point concentrated by a lens | Throughout the tissue the current flows through — heat generated inside by tissue resistance |
| Shape of the heat | Point-by-point coagulation points at a set depth | Relatively broad volume, evenly |
| What sets the depth | A fixed focal depth for each cartridge (transducer) | Electrode size · arrangement, polarity (monopolar · bipolar), frequency |
| Epidermal protection | Focus forms beneath the epidermis | Relies on cooling (gas · contact cooling etc.) |
“Ultrasound is deeper, so it’s stronger” is only half right. Depth is set by cartridge · electrode settings rather than the name of the technology, and deeper doesn’t mean better. Where the layer you want to treat lies comes first. The principles are covered in detail in Focused ultrasound (HIFU) and radiofrequency (RF) — not competing technologies.
What devices does Miso Clinic have, and not have?
| Device | Method | Miso Clinic |
|---|---|---|
| Density (Jeisys Medical) | Monopolar → bipolar sequential radiofrequency, 5-level gas cooling | Yes |
| XERF (Lutronic) | Monopolar radiofrequency, 6.78 MHz + 2 MHz | Yes |
| Oligio Kiss (Wontech) | Combined device of monopolar radiofrequency (Oligio) + focused ultrasound (Ultraskin Titan) | Yes |
| Ulthera · Shrink etc. | Dedicated focused ultrasound devices | No |
| Thermage · ONDA lifting · Titanium | Lifting devices of other types | No |
Oligio Kiss is a device approved by the MFDS on 1 September 2023 under the name The Great RF Sonata, and per the approval information it contains radiofrequency and focused ultrasound in one unit. So writing “Miso Clinic has no ultrasound at all” would be inaccurate. Precisely, we have no dedicated device using focused ultrasound alone. I’ll also note that no human study of the finished Oligio Kiss device itself has been confirmed. Details are in Why Oligio Kiss puts the two in one device.
If you want Ulthera · Shrink · Thermage, it’s right to consult a place that has those devices. Those devices appear in this piece for comparison.
How far has the evidence for focused ultrasound come?
Focused ultrasound has a lot of data given its long use, but little of it is controlled. In a meta-analysis pooling 42 studies, there were 2 controlled clinical studies, evidence level 3, with practitioner-rated improvement 89% · patient-rated 84%, and mean pain 4.85/10 (Amiri 2025). In the same review, satisfaction split between 62% and 91% depending on whether the questionnaire had a “neutral” option.
There is also a trial randomly comparing the leading device, Ulthera, with a group receiving no treatment. With 101 treated vs 100 untreated, blinded photo judgement of improvement at 90 days after one session was 54.2% vs 47.0%, odds ratio 1.35 (95% confidence interval 0.75–2.44), not statistically significant (NCT04795622, registered by the manufacturer). In the same trial, unblinded practitioner assessment was 96.8% and patient assessment 94.7%.
This result doesn’t mean “focused ultrasound doesn’t work.” It means it failed to show a difference from the untreated group under the conditions of one session · 90 days · photo judgement. In the US, clinical data on 167 people from 7 studies were submitted for an indication of lifting brow · submental · neck tissue (K243035). There is also a systematic review of focused ultrasound (ASJ 2025;45(7):690), but we couldn’t check the full text directly, so we haven’t carried over figures. The evidence on Ulthera is set out separately in How far has the evidence for Ulthera come?.
How far has the evidence for radiofrequency come?
Radiofrequency isn’t much different. A 2026 systematic review pooled 15 studies · 1,230 people, but only 1 was a randomised controlled trial, and it noted that no direct device-to-device comparison study was found (ASJ Open Forum 2026).
| Device | Data | Limitations |
|---|---|---|
| Density | 16 people · 1 session · 24 weeks, 3D imaging tightening 0.82 mm, pain 1.4/5 (Oku 2025) | No control group · single author |
| XERF | Three studies of 20 · 39 · 16 people (Hwang 2025 · Weiss 2026 · Erlich 2026) | None with a control group; the 39-person study manufacturer-supported |
| Oligio (Kiss’s radiofrequency axis) | 20 women · 1 session; significant improvement in jawline · nasolabial folds at 12 weeks; pain 0.4/10 (Cosmetics 2024) | No control group · not a study of the finished Kiss device |
In sum, focused ultrasound has controlled trials, so its limits can be seen; radiofrequency has almost no controlled trials, so even its limits haven’t been measured. Neither has data to say it is “definitely better.”
Why do practitioner and patient assessments come out so differently?
When reading numbers in lifting studies, always look at who assessed. In a review of 16 ultrasound lifting studies, improvement at 90 days was 92% by practitioner assessment and 42% by patient assessment. In a study following 20 people for a year, blinded assessment was 43% while patient satisfaction was 95–100%, and quantitatively measured lift peaked at 90 days and fell to 22–33% of that at one year (IJERPH 2023 · Werschler 2016).
In the Ulthera trial above, too, there was a large gap between unblinded practitioner assessment at 96.8% and blinded judgement at 54.2%. Most radiofrequency device data lacks even a control group to measure this gap. So “9X% satisfaction” in promotional material can hardly ground a device comparison. The habit of checking the assessor matters more than the device name.
So how should I choose?
With no direct comparison data, Miso Clinic sorts not by device name but by what has changed in the face (clinical judgement).
| Main change | Look at first | Reason |
|---|---|---|
| Dermis thinned, elasticity · texture breaking down | Radiofrequency (Density · XERF) | Heating a broad volume suits the dermis as a whole |
| Jawline · cheek tissue descending | Radiofrequency; thread lifting if needed | Tightening or hooking and lifting |
| Wanting to tighten a specific depth layer point by point | Oligio Kiss (radiofrequency + focused ultrasound) or a place with a dedicated HIFU device | Miso Clinic has no dedicated HIFU device |
| Hollow cheeks · temples | No device — filler · collagen boosters | Heat can’t fill volume |
| Skin loose enough to fold | Surgical consultation | Outside the range of non-surgical devices |
This table isn’t a research result but a judgement from mechanism and examination. The hub piece comparing all devices at once is Lifting in Daegu: which device to choose?, and choosing between Density and XERF is in Density or XERF.
What should I ask at the consultation?
- Is the main problem in my face sagging, hollowing or thinned skin?
- Is the device you recommend radiofrequency, focused ultrasound, or a device combining the two?
- Do that device’s human studies have a control group? Who did the assessment?
- When are results judged? Is it OK to judge by the face the next day?
- Can I see the approval information of the device used today?
For radiofrequency there is data that clinical assessment was not significant at 4 weeks and significant at 12, with a peak at 4–6 months (Cosmetics 2024 etc., all without control groups). So Miso Clinic looks at results together not with the face the day after treatment but months later (clinical judgement). To check approval numbers, see How to look up approval numbers directly.
Ultrasound (HIFU) and radiofrequency: frequently asked questions
Which is more effective, HIFU or radiofrequency?
We found no study comparing the two under the same conditions. A systematic review of radiofrequency also noted no direct device-to-device comparisons. So rather than by device, we sort by whether the problem is sagging · hollowing · thinning.
Can I get Ulthera or Shrink at Miso Clinic?
No. Miso Clinic has no dedicated focused ultrasound devices such as Ulthera · Shrink. Our lifting devices are Density · XERF · Oligio Kiss.
Is Oligio Kiss an ultrasound device or a radiofrequency device?
Both. Per the approval information, it’s a combined device with monopolar radiofrequency (Oligio) and focused ultrasound (Ultraskin Titan) in one unit. No human study of the finished device itself has been confirmed.
Since HIFU goes deeper, does it lift better?
Depth is set by cartridge · electrode settings rather than the technology’s name, and deeper doesn’t mean better. Where the layer you want to treat lies comes first.
Hasn’t Ulthera been proven effective?
In a randomised trial against an untreated group, blinded photo judgement after 1 session · 90 days was 54.2% vs 47.0%, with no significant difference. It means less that it doesn’t work than that it failed to show a difference under those conditions.
Where can I get a consultation on HIFU and radiofrequency lifting in Daegu?
Miso Clinic in Daegu is at 4F Bombom Building, 125 Dongdeok-ro, Jung-gu, Daegu, in front of Exit 1 of Kyungpook National University Hospital Station. +82-53-428-2700; weekdays 11:00–19:00 · Saturday 10:00–16:00 (no lunch break); closed Sundays · public holidays.
Clinical columns to read next
- Lifting in Daegu: which device to choose
- Density or XERF
- The difference between Density and Thermage
- Focused ultrasound (HIFU) and radiofrequency (RF) — not competing technologies
- Ulthera · Thermage vs Density · XERF: the differences
- How far has the evidence for Ulthera come?
- Why Oligio Kiss puts the two in one device
Product reference
Device references: Density · XERF · Oligio Kiss
Clinic
This column was written and reviewed by Lee Chi-Hak, MD, medical director of Miso Clinic in Daegu. The treatment criteria and injection design are written exactly as we actually use them.
| Medical Director | Lee Chi-Hak, MD |
|---|---|
| Address | 4F Bombom Building, 125 Dongdeok-ro, Jung-gu, Daegu (Exit 1, Kyungpook National University Hospital Station) · tower parking in the building |
| Phone | 053-428-2700 |
| KakaoTalk consultation | Miso Clinic Daegu channel |
| KakaoTalk channel | Add the channel |
| Opening hours | Weekdays 11:00–19:00 (lunch 13:00–14:00) / Saturday 10:00–16:00 (no lunch break) / Closed Sundays and public holidays |
| Clinical column | See all columns |
| Reference library | All booster and lifting device references |
References
- Ulthera untreated-control randomised trial — NCT04795622 (registered by manufacturer Merz · results posted). 5 sites in China, 101 treated vs 100 untreated, 1 session, 90 days. Blinded photo judgement 54.2% vs 47.0%, odds ratio 1.3545 (95% CI 0.7530–2.4365) — not statistically significant. Unblinded practitioner assessment 96.8% · patient assessment 94.7%.
- Focused ultrasound meta-analysis — Amiri M et al., Aesthetic Surg J 2025;45(3):NP86–NP94. 42 studies (2 controlled clinical studies), evidence level 3. Practitioner-rated improvement 89% · patient 84% · mean pain 4.85/10. Satisfaction 62% vs 91% depending on whether a “neutral” option was offered.
- Systematic literature review of focused ultrasound — Aesthetic Surgery Journal 2025;45(7):690, DOI 10.1093/asj/sjaf053. A review covering applications in skin tightening · body contouring. We couldn’t check the full text directly, so we haven’t cited its figures.
- Improvement rates that differ by assessor — review of 16 ultrasound lifting studies (IJERPH 2023;20(2):1522): day 90, practitioners 92% vs patients 42%. Werschler 2016 (20 people): 1-year blinded assessment 43% vs patient satisfaction 95–100%; quantitative lift peaked at 90 days · fell to 22–33% at 1 year.
- Ulthera’s US 510(k) — K243035 (2025-02-24). Indication wording on lifting brow · submental · neck tissue; clinical data from 7 studies, 167 people submitted. XERF K251327’s indication is electrocoagulation · haemostasis, with no clinical data submitted.
- Evidence comparing RF devices — Aesthetic Surgery Journal Open Forum 2026 systematic review (15 studies · 1,230 people, 1 randomised controlled trial). States that no head-to-head device comparisons were found.
- Human study of Density — Oku K, J Cosmet Dermatol 2025;24(10):e70504, PMID 41090512. 16 adults · one session · 24 weeks · no control group. 3D imaging tightening distance 0.82 ± 0.36 mm, pain 1.4 ± 0.6 (5-point scale).
- Three human studies of XERF — Hwang JK, Medical Lasers 2025;14(1):23–30 (20 people · one session · 12 weeks) · Weiss RA et al., Cureus 2026;18(3):e104546, PMID 41930066 (39 people · two sessions · 90 days, manufacturer-supported) · Erlich G et al., Lasers Med Sci 2026;41(1), PMID 42611100 (retrospective 16 people · one session · 3 months). None of the three had a control group.
- Study in the monopolar radiofrequency family — Cosmetics 2024;11(3):71, DOI 10.3390/cosmetics11030071. 20 women (mean 47.95 ± 6.02 years, Fitzpatrick III–IV) · 1 session · assessed at 4 · 12 · 24 weeks · assessor blinded · no control group. Significant improvement of jawline · nasolabial folds at 12 weeks; mean pain 0.4/10. Not a study using Oligio Kiss (radiofrequency + focused ultrasound), and doesn’t apply as is to pain from treatments including focused ultrasound.
- Oligio Kiss approval — MFDS medical device approval information. Product name The Great RF Sonata (Wontech), approved 1 September 2023. Marketed as ‘Oligio Kiss’, launched in Korea in February 2024 (Wontech product information). Consists of monopolar radiofrequency (Oligio) + focused ultrasound (Ultraskin Titan).
- Density specifications — Jeisys Medical published material: sequential monopolar → bipolar delivery, up to 400 W, RIC automatic impedance adjustment, 5-level gas cooling, real-time skin temperature, tips ALPHA 600 · Eye 600 · Face 1,000 · Body 600 shots (guaranteed shot counts). MFDS-approved medical device; approval number not confirmed in the original.
- XERF specifications — Lutronic published material: monopolar, 6.78 MHz + 2 MHz, handpieces i05 (5×10 mm · 400 shots) · i10 (10×10 mm · 300 shots) · E40 (20×20 mm · 600 shots) · E60 (20×30 mm · 600 shots). Korean approval classification: general-purpose electrosurgical unit; advertising review “General-purpose electrosurgical unit association-2024-16-054”.
- Timeline of RF results — Cosmetics 2024;11(3):71 (20 Korean women: clinical assessment not significant at 4 weeks · significant at 12 · 24 weeks; device-measured elasticity from 4 weeks) · Weiss 2026 (84.6% at 30 days → 92.3% at 90 days) · Fitzpatrick 2003 and Edwards AF et al., Dermatol Surg 2013;39:104–110 (peak at 4–6 months). None had a control group.
- Korean medical advertising law — Medical Service Act Article 56(2), which prohibits testimonial advertising, comparison with other medical institutions and superlative claims.
- Miso Clinic clinical guidelines — criteria for indications, design by area, pre-treatment explanation and consent. The source of sentences marked “clinical judgement” in this column.
Everything in this column is general information and does not replace medical diagnosis or treatment. Effects and side effects vary with individual skin condition, age and underlying illness, and the same result is not guaranteed for everyone. Any decision to proceed should be made in an in-person consultation with a physician.